Publicaciones (19) Publicaciones de MARIA BELEN FERNANDEZ LLANA

2021

  1. PET/CT with 18F-Fluordesoxyglucose in patients with suspected endovascular prosthesis infection

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 40, Núm. 1, pp. 12-18

  2. SARS-CoV-2 (COVID-19) pneumonia: Incidental finding on 18F-FDG PET/CT study for vasculitis diagnosis

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 40, Núm. 4, pp. 251-252

2020

  1. Isolated Immunoglobulin G4-Related Disease of Nasal Septum and Maxilla: Diagnosis and Follow-up with 18F-FDG PET/CT

    Clinical Nuclear Medicine, Vol. 45, Núm. 2, pp. e122-e124

2019

  1. Late-onset Cogan's syndrome associated with large-vessel vasculitis

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. e30-e32

1996

  1. CYFRA 21.1 CITOSOLICO Y PROLIFERACION CELULAR EN CARCINOMAS DUCTALES INFILTRANTES DE MAMA

    Revista Espanola de Medicina Nuclear

  2. CYFRA 21.1 cytosolic levels in breast diseases. Correlation with other clinical and biological parameters [1]

    International Journal of Biological Markers

1995

  1. Cytosolic tissue-type plasminogen activator (t-PA) levels in ductal infiltrating carcinomas of the breast classified according to different clinical and biological parameters.

    International Journal of Biological Markers

1994

  1. Cytosolic tissue-type plasminogen activator (t-PA) levels in breast tumors and hormone dependence. Role of pS2 [1]

    International Journal of Biological Markers

1993

  1. CAM26 cytosol levels seem to be correlated with pS2 expression in breast cancer.

    International Journal of Biological Markers

  2. Placental serum alkaline phosphatase, defined by monoclonal antibody C2, in non-malignant diseases and in non-germinal tumors.

    International Journal of Biological Markers

1992

  1. CAM26 and CAM29 cytosol levels in breast tumors classified according to estrogen receptor status. First results.

    International Journal of Biological Markers

  2. Estudio de las concentraciones citosólicas de CAM29 en carcinomas de mama. Influencia de la pS2.

    Revista Clinica Espanola

  3. Experiencia preliminar del BCM-IMx como marcador de los tumores mamarios pretratamiento.

    Revista Clinica Espanola

  4. Proteína oncogénica neu citosólica dosificada mediante un enzimoinmunoanálisis: aproximación a un dintel de aplicación clínico.

    Revista Clinica Espanola

  5. Total lactate dehydrogenase and tumor necrosis factor alpha levels in cyst fluid of women with gross cystic breast disease.

    International Journal of Biological Markers

1991

  1. BCM-IMx and CA15.3 serum levels in patients with breast cancers. Comparative study

    Bulletin du Cancer, Vol. 78, Núm. 8, pp. 743-745

  2. BCM-IMx behaviour in patients with lung diseases

    Bulletin du Cancer, Vol. 78, Núm. 9, pp. 843-845

  3. Different immunoreactivity between cyst fluid and serum prolactin in women with cystic breast disease.

    International Journal of Biological Markers

  4. Serum BCM-IMx levels in 376 patients with non-malignant diseases.

    International Journal of Biological Markers